

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	2
INTENDED AUDIENCE.....	2
SCOPE OF REPORT.....	3
METHODOLOGY.....	3
INFORMATION SOURCES.....	4
AUTHOR'S CREDENTIALS.....	4
RELATED BCC REPORTS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER.....	5
 CHAPTER TWO: SUMMARY.....	 6
SUMMARY.....	6
<i>SUMMARY TABLE GLOBAL MARKET FOR MS DISEASE-</i> <i>MODIFYING PRODUCTS, THROUGH 2015 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR THERAPIES TREATING</i> <i>MS, 2008-2015 (\$ MILLIONS)</i>	8
 CHAPTER THREE: OVERVIEW.....	 9
DISEASE CHARACTERISTICS.....	9
HISTORY AND DISCOVERY OF MS.....	9
SYMPTOMS OF MS.....	10
PREVALENCE AND INCIDENCE OF MS.....	10
<i>TABLE 1 MS STATISTICS FROM AROUND THE WORLD, 2008</i>	11
DIAGNOSIS OF MS.....	12
DIAGNOSIS OF MS (CONTINUED).....	13
TYPES OF MS.....	14
PROGNOSIS.....	15
TREATMENTS FOR MS.....	16
TYPES OF MS THERAPIES.....	16
<i>TABLE 2 CURRENTLY APPROVED MS THERAPIES ON THE</i> <i>MARKET</i>	17
<i>TABLE 3 FEATURES OF SMALL MOLECULE VERSUS BIOLOGIC MS</i> <i>DISEASE-MODIFYING THERAPIES</i>	17
<i>TABLE 3 (CONTINUED)</i>	18
<i>TABLE 4 WHOLESALE ACQUISITION COST OF SELECTED</i> <i>THERAPIES FOR MS, 2009 (\$)</i>	19
TARGETS OF MS THERAPIES.....	19
VLA-4 (CD49D AND CD29).....	19
S1P.....	20
CD20.....	21
IL-2 (CD25, CD122, AND CD132).....	21
CD52.....	22
MYELIN BASIC PROTEIN-REACTIVE T-CELLS.....	22

SIDE EFFECTS OF MS THERAPIES.....	23
TABLE 5 COMPARISON OF SIDE EFFECT PROFILES OF MARKETED AND LATE-CLINICAL STAGE THERAPIES FOR MS.....	23
MS THERAPIES IN CLINICAL DEVELOPMENT	24
TABLE 6 MS THERAPIES IN CLINICAL TRIALS, ORDERED BY PHASE.....	24
TABLE 6 (CONTINUED).....	25
TABLE 6 (CONTINUED).....	26
TABLE 7 MS THERAPIES IN DEVELOPMENT, BY PHASE (NUMBER/%).....	26
FIGURE 1 MS THERAPIES IN ACTIVE CLINICAL TRIALS BY PRIMARY TARGET (NUMBER)	26
FIGURE 1 (CONTINUED)	27
TABLE 8 COMPANIES WITH MORE THAN ONE MS THERAPY IN ACTIVE CLINICAL TRIALS OR ON THE MARKET*	27
CLINICAL TRIAL EFFICACY OUTCOME MEASUREMENTS IN MS STUDIES.....	28
Relapse Rate	28
EDSS	28
Gadolinium-Enhanced (GdE) Lesions on MRI	29
TABLE 9 EFFICACY RESULTS OF MS DISEASE-MODIFYING THERAPIES	30
CHAPTER FOUR: TECHNOLOGY.....	31
OVERVIEW.....	31
TABLE 10 GLOBAL MARKET FOR MS DISEASE-MODIFYING THERAPIES BY CLASS, THROUGH 2015 (\$ MILLIONS)	31
TABLE 11 GLOBAL SALES OF MS DISEASE-MODIFYING THERAPIES BY FORMULATION, THROUGH 2015 (\$ MILLIONS).....	32
TABLE 12 ADMINISTRATION PROFILES OF THERAPIES APPROVED TO TREAT MS.....	32
CHAPTER FIVE: PATENT EVALUATION.....	33
PATENT LENGTH AND MARKET EXCLUSIVITY	33
ORPHAN DRUG EXCLUSIVITY.....	33
REBIF AND AVONEX'S ORPHAN DRUG MARKETING EXCLUSIVITY.....	34
TABLE 13 U.S. PATENT EXPIRATION DATES OF THERAPIES FOR MS ON THE MARKET OR IN PHASE III DEVELOPMENT.....	34
TABLE 13 (CONTINUED).....	35
BIOGEN IDEC AND THE INTERFERON BETA PATENTS	35
SMALL MOLECULE MS DISEASE-MODIFYING PRODUCTS AND GENERIC DRUGS	36
CHAPTER SIX: SMALL MOLECULE MS DRUGS	37

MARKET OVERVIEW	37
TABLE 14 GLOBAL MARKET FOR SMALL MOLECULE MS DISEASE-MODIFYING DRUGS BY INDIVIDUAL DRUG, THROUGH 2015 (\$ MILLIONS).....	38
SMALL MOLECULE MS DISEASE-MODIFYING DRUGS	39
COPAXONE (GLATIRAMER ACETATE, COPOLYMER 1)	39
TABLE 15 COPAXONE PIVOTAL STUDY RESULTS	40
Copaxone (Continued)	41
TABLE 16 GLOBAL MARKET FOR COPAXONE BY REGION, THROUGH 2015 (\$ MILLIONS).....	42
NOVANTRONE (MITOXANTRONE)	42
Novantrone (Mitoxantrone) (Continued)	43
TABLE 17 GLOBAL MARKET FOR NOVANTRONE BY REGION, THROUGH 2015 (\$ MILLIONS).....	44
M356 (GLATIRAMER ACETATE)	44
M356 (Glatiramer Acetate) (Continued).....	45
GILENIA (FINGOLIMOD, FTY720).....	46
Gilenia (Fingolimod, FTY720) (Continued)	47
TABLE 18 GILENIA PIVOTAL PHASE III STUDY RESULTS.....	48
Gilenia (Fingolimod, FTY720) (Continued)	49
TABLE 19 GLOBAL MARKET FOR GILENIA BY REGION, THROUGH 2015 (\$ MILLIONS).....	50
LAQUINIMOD (ABR-215062)	50
TABLE 20 LAQUINIMOD PIVOTAL PHASE III STUDIES	51
Laquinimod (ABR-215062) (Continued)	52
TABLE 21 GLOBAL MARKET FOR LAQUINIMOD BY REGION, THROUGH 2015 (\$ MILLIONS).....	53
MYLINAX, MOVECTRO (ORAL CLADRIBINE).....	54
Mylinax, Movectro (Oral Cladribine) (Continued)	55
Mylinax, Movectro (Oral Cladribine) (Continued)	56
Mylinax, Movectro (Oral Cladribine) (Continued)	57
TABLE 22 GLOBAL MARKET FOR MYLINAX, BY REGION, THROUGH 2015 (\$ MILLIONS).....	58
TERIFLUNOMIDE (HMR1726)	58
TABLE 23 GLOBAL MARKET FOR TERIFUNOMIDE BY REGION, THROUGH 2015 (\$ MILLIONS).....	59
BG-12 (DIMETHYL FUMARATE, BG00012).....	60
TABLE 24 GLOBAL MARKET FOR BG-12 BY REGION, THROUGH 2015 (\$ MILLIONS).....	61
FIRATEGRAST (SB683699, T-0047).....	62
BAF312	62
ONO-4641	63
ACT-128800	63
MASITINIB	64

PLENEVA (BGC20-0134)	65
TRIMESTA (ESTRIOL)	65
KETAS (MN-166, AV-411, IBUDILAST)	66
TABLE 25 MN-166 PHASE II STUDY RESULTS	67
ELND002	68
PI-2301	68
CS-0777	69
CDP323 (UCB-323)	69
DIRUCOTIDE (MBP8298)	69
CHAPTER SEVEN: BIOLOGICS FOR MS	70
OVERVIEW	70
TABLE 26 BIOLOGICS FOR MS BY CLASS	71
TABLE 27 GLOBAL MARKET FOR BIOLOGIC FOR MS BY INDIVIDUAL DRUG, THROUGH 2015 (\$ MILLIONS)	71
MABS ANTIBODIES FOR MS	71
TABLE 28 BENEFITS AND CHARACTERISTICS OF MABS	72
TABLE 29 SELECTED ANTIBODIES IN DEVELOPMENT FOR MS	73
TYSABRI (NATALIZUMAB)	73
TABLE 30 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS	74
Tysabri (Natalizumab) (Continued)	75
Tysabri (Natalizumab) (Continued)	76
TABLE 31 GLOBAL MARKET FOR TYSABRI BY REGION, THROUGH 2015 (\$ MILLIONS)	77
CAMPATH/MABCAMPATH (ALEMTUZUMAB)	77
Campath/MabCampath (Alemtuzumab) (Continued)	78
TABLE 32 ALEMTUZUMAB PHASE II STUDY RESULTS	79
Campath/MabCampath (Alemtuzumab) (Continued)	80
TABLE 33 GLOBAL MARKET FOR CAMPATH IN MS BY REGION, THROUGH 2015 (\$ MILLIONS)	81
ZENAPAX (DACLIZUMAB)	81
TABLE 34 DACLIZUMAB CHOICE STUDY RESULTS	82
Zenapax (Daclizumab) (Continued)	83
TABLE 35 GLOBAL MARKET FOR DACLIZUMAB IN MS BY REGION, THROUGH 2015 (\$ MILLIONS)	84
RITUXAN, MABTHERA (RITUXIMAB)	84
Rituxan, MabThera (Rituximab) (Continued)	85
OCRELIZUMAB (RG1594, PRO70769)	86
ARZERRA (OFATUMUMAB)	87
AIN457	87
LY2127399	88
ABT-874	89
BIIB033	89
ANTI-CD100 MAB	89
USTEKINUMAB (CNTO1275)	90

INTERFERON BETAS	90
INTERFERON BETAS (CONTINUED).....	91
<i>TABLE 36 GLOBAL MARKET FOR INTERFERON BETAS IN MS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>92</i>
BETASERON, BETAFERON (INTERFERON BETA-1B, BAY86-5046)	92
<i>TABLE 37 TWO-YEAR BETASERON RRMS STUDY RESULTS</i>	<i>93</i>
<i>TABLE 38 THREE-YEAR BETASERON RRMS STUDY RESULTS</i>	<i>94</i>
<i>TABLE 39 GLOBAL MARKET FOR BETASERON BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>95</i>
AVONEX (INTERFERON BETA-1A)	95
<i>TABLE 40 AVONEX PIVOTAL PHASE III STUDY RESULTS</i>	<i>96</i>
<i>TABLE 41 GLOBAL MARKET FOR AVONEX BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>97</i>
REBIF (INTERFERON BETA-1A).....	98
Rebif (Interferon Beta-1A) (Continued).....	99
<i>TABLE 42 GLOBAL MARKET FOR REBIF BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>100</i>
EXTAVIA (INTERFERON BETA-1B).....	100
Extavia (Interferon Beta-1b) (Continued)	101
<i>TABLE 43 GLOBAL MARKET FOR EXTAVIA BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>102</i>
CINNOVEX (INTERFERON BETA-1A)	102
BIFERONEX (INTERFERON BETA-1A).....	102
Biferonex (Interferon Beta-1a) (Continued)	103
PEG INTERFERON BETA-1A, BIIB017).....	104
TV-1390.....	105
THERAPEUTIC VACCINES	105
TOVAXIN	106
ATX-MS-1467	107
RTL1000	108
BHT-3009.....	108
NEUROVAX	109
XTOLL (CHAPERONIN 10, CPN10)	109
XToll (Chaperonin 10, Cpn10) (Continued).....	110
NTX-488 (PROLACTIN)	111
ATL1102 (FORMERLY TV-1102).....	111
ATL1102 (formerly TV-1102) (Continued)	112
CHAPTER EIGHT: DISEASE APPLICATIONS	113
OVERVIEW.....	113
<i>TABLE 44 LABELS OF APPROVED DISEASE-MODIFYING THERAPIES FOR MS</i>	<i>114</i>
<i>TABLE 44 (CONTINUED)</i>	<i>115</i>
MS SUBGROUPS	116

RRMS	116
SPMS	116
PPMS	117
PPMS (Continued)	118
PRMS	119
THE MARKET FOR MS THERAPIES BY MS DISEASE SUBGROUP CLASSIFICATION	119
CHAPTER NINE: MAJOR COMPANIES AND MARKET SHARE.....	120
MARKET SHARE	120
<i>TABLE 45 FORECASTED SALES AND MARKET SHARE OF COMPANIES WITH AGENTS FOR MS ON THE MARKET, 2010 AND 2015 (\$ MILLIONS/%)</i>	120
COMPANY PROFILES	121
AB SCIENCE.....	122
AB Science USA.....	122
ABBOTT LABORATORIES.....	122
ACTELION	123
ACTIVE BIOTECH	124
ADEONA PHARMACEUTICALS	124
ANTISENSE THERAPEUTICS	125
APITOPE	125
ARTIELLE IMMUNOTHERAPEUTICS	126
BAYER AG	127
Bayer (U.S. Location)	127
BIOGEN IDEC	128
BTG.....	129
CBIO	130
CINNAGEN.....	130
DAIICHI SANKYO.....	131
ELAN	131
ELI LILLY	132
FAST FORWARD, LLC.....	132
FIVE PRIME THERAPEUTICS.....	133
GENMAB.....	134
Genmab (U.S. Location)	134
GENZYME.....	134
GLAXOSMITHKLINE	135
GlaxoSmithKline (U.S. Location)	135
MEDICINOVA.....	136
MERCK KGAA (MERCK SERONO).....	137
MITSUBISHI TANABE PHARMA.....	138
MOMENTA PHARMACEUTICALS.....	138
NOVARTIS	139
ONO PHARMA.....	140

OPEXA THERAPEUTICS	141
PEPTIMMUNE	141
PFIZER	142
ROCHE	143
SANOFI-AVENTIS	143
STEM CELL THERAPEUTICS.....	144
TEVA PHARMACEUTICAL INDUSTRIES	145
CHAPTER TEN: INTERNATIONAL ASPECTS AND REGULATORY ISSUES	146
MARKET BY REGION	146
<i>TABLE 46 GLOBAL FORECAST FOR MS DISEASE-MODIFYING THERAPIES BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	146
MARKET BY REGION (CONTINUED).....	147
UNITED STATES	148
The FDA Modernization Act of 1997	148
Fast-Track Status.....	149
Special Protocol Assessments	149
New Surveillance and Safety Requirements.....	150
Approvable Letters	151
Consumer Confidence.....	151
Medicare.....	151
Other Healthcare Changes.....	152
EUROPEAN UNION	153
New Drug Approvals and Innovation	153
Drug Reimbursement and Reference Pricing.....	154
Relocation of R&D	155
JAPAN	156
New Drug Approvals	156
Regulatory Climate.....	156
Relationship between Academia and Industry	157
CHAPTER ELEVEN: FUTURE DIRECTIONS.....	158
THE ROLE OF BIOMARKERS AND PHARMACOGENOMICS.....	158
COMBINATION THERAPIES.....	159
THE EFFECT OF GENERIC MS THERAPIES ON PRICE	160
THE EFFECT OF GENERIC MS THERAPIES ON PRICE (CONTINUED).....	161